In silico subtractive genomics and reverse vaccinology approach reveal outer membrane proteins OMP47 and LptD as dual-purpose drug and vaccine targets in Pasteurella multocida Pm70

Bacteria are single-celled organisms that have evolved to survive in almost every environment on Earth, including inside the human body. While many are harmless or even helpful, some are dangerous pathogens that cause serious illness. When these harmful bacteria infect us, doctors typically treat them with antibiotics, drugs designed to kill the bacteria or stop them from multiplying. However, bacteria are clever and adaptable; over time, many have learned to resist these medicines, rendering standard treatments ineffective. This growing resistance makes finding new ways to fight bacterial infections one of the most urgent challenges in modern medicine. To solve this, scientists are increasingly turning to computers to design new medicines and vaccines. Instead of testing thousands of chemicals in a lab, they use powerful software to scan the entire genetic code of a bacterium, looking for specific weaknesses that can be targeted without harming the human host. This approach allows researchers to identify the most promising candidates for new drugs and vaccines before ever stepping into a laboratory.

A bacterium called Pasteurella multocida is a prime example of a pathogen that is becoming harder to treat. This germ lives in the mouths of many animals, particularly cats and dogs, and can be passed to humans through bites or scratches. While often causing minor skin infections, it can lead to severe pneumonia, blood infections, and other life-threatening conditions, especially in people with weakened immune systems. The problem is that this bacterium is developing resistance to many common antibiotics, and there is currently no vaccine approved for humans to prevent it. Faced with this rising threat, a team of researchers set out to find new ways to stop the bacteria using a method called subtractive genomics. This process is like a game of elimination: the scientists start with the complete list of every protein the bacterium makes and systematically remove any that look too similar to proteins found in humans. The goal is to find proteins that are essential for the bacteria's survival but are unique to the germ, ensuring that a drug targeting them would kill the bacteria without hurting the person.

From the thousands of proteins in the Pasteurella multocida genome, the researchers whittled the list down to just 129 proteins that are critical for the bacteria to live and have no human equivalent. They then looked deeper, checking which of these 129 proteins were located on the outer shell of the bacterium, making them accessible to drugs and the immune system. This rigorous filtering process narrowed the field to two specific proteins: a 47-kilodalton outer membrane protein, known as OMP47, and a protein called LptD, which acts as a builder for the bacterium's outer wall. These two proteins stood out because they are not only vital for the bacteria's survival but also sit on the surface where they can be easily reached. The researchers found that OMP47 helps the bacteria stick to surfaces and move materials across their membrane, while LptD is responsible for assembling the outer layer of the cell, a process that is crucial for the bacterium's structural integrity. Because these proteins are so important to the bacteria's life and are exposed on the outside, they represent ideal targets for both new medicines and vaccines.

To see if these proteins could also serve as the basis for a vaccine, the team used computer models to predict how the human immune system would react to them. They broke down the two proteins into tiny fragments called epitopes, which are the specific parts that the immune system recognizes as foreign. The researchers selected the most promising fragments—those that were likely to trigger a strong immune response but were safe for humans, meaning they were not toxic or likely to cause allergic reactions. They then stitched these selected fragments together, along with a special helper molecule called an adjuvant, to create a single, custom-designed vaccine candidate. This new vaccine, known as a multi-epitope vaccine, is a synthetic construct made entirely of the most effective parts of the bacterial proteins, designed to teach the immune system to recognize and fight the real bacteria.

The researchers then tested this virtual vaccine using advanced computer simulations to see how it would behave. They modeled the three-dimensional shape of the vaccine and checked its stability, confirming that it held together well and had the right chemical properties to be produced in a lab. They simulated how the vaccine would interact with the human immune system, specifically looking at how it would bind to a key receptor called TLR4, which acts as an alarm bell for the body's defenses. The simulations showed a very strong and stable connection between the vaccine and this receptor, suggesting it would effectively wake up the immune system. Furthermore, the computer models predicted that after receiving the vaccine, the body would produce a robust defense, including the creation of memory cells that would remember the bacteria and fight it off if encountered again in the future. The team also confirmed that the genetic code for this vaccine could be easily adapted to be manufactured in common laboratory bacteria, making it feasible to produce in large quantities.

While these findings are promising, the researchers are careful to note that this work is currently a sophisticated computer simulation. The study has successfully identified two proteins that are excellent candidates for drug development and has designed a vaccine that looks perfect on paper, but these results have not yet been tested in living cells or animals. The next step would be to create the vaccine in a real laboratory and test it to see if it works as the computers predicted. If future experiments confirm these results, the two identified proteins could lead to new antibiotics that bypass current resistance, and the designed vaccine could provide the first human protection against this widespread and dangerous infection. Until then, this work serves as a solid foundation, proving that computer science can effectively guide the search for new ways to protect human health from bacterial threats.